Effectiveness of therapeutic lifestyle changes in patients with hypertension, hyperlipidemia, and/or hyperglycemia
Section snippets
Acknowledgment
We thank the following individuals for invaluable assistance with this study: Kimberly Allen, RD, Julie Blakely, BS, Chip Faircloth, MHA, Terri Gordon, Sharon Johnson, Scott Kallish, MA, Ivan Levinrad, RPT, Brenda Wright, PhD, Kevin Reid, MA, Shirley Salmon, BA, Tom Savona, MA, William Saxon, ASRT, Robert Skiljan, MS, Crystal Steele, BS, and John Thiel, MA.
References (18)
- et al.
Effectiveness of three models for comprehensive cardiovascular disease risk reduction
Am J Cardiol
(2002) - et al.
Can lifestyle changes reverse heart disease? The Lifestyle Heart Trial
Lancet
(1990) - et al.
Prevalence of conventional risk factors in patients with coronary heart disease
JAMA
(2003) - et al.
Major risk factors as antecedents of fatal and nonfatal coronary heart disease events
JAMA
(2003) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
JAMA
(2001)- et al.
AHA guidelinesEvidence-based guidelines for cardiovascular disease prevention in women
Circulation
(2004) - et al.
Innovative approaches to comprehensive cardiovascular disease risk reduction in clinical and community-based settings
Curr Atheroscler Rep
(2001) - et al.
AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update
Circulation
(2001) - et al.
AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update
Circulation
(2002)
Cited by (47)
Relationship between Risk Factor Control and Compliance with a Lifestyle Modification Program in the Stenting Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis Trial
2018, Journal of Stroke and Cerebrovascular DiseasesCitation Excerpt :The SAMMPRIS Trial was also the first vascular disease prevention trial to incorporate a commercially available telephonic lifestyle modification program for study participants to enhance risk factor control. Although lifestyle modification programs have improved the achievement of risk factor targets in a variety of clinical settings, including patients who have previously suffered a stroke or transient ischemic attack,5-7 to our knowledge, such programs have not been evaluated in the setting of a vascular prevention clinical trial. In the present study, we sought to determine if utilization of a lifestyle modification program improved risk factor control in the setting of a clinical trial.
Metabolic syndrome reversal through nutrition: A case report
2016, Advances in Integrative MedicineTherapeutic education in primary cardiovascular prevention. Interests and limits
2014, Annales de Cardiologie et d'AngeiologieMedical management of asymptomatic carotid stenosis
2012, Perspectives in MedicineCitation Excerpt :Further evidence for efficacy of best medical treatment was gained by evaluation of the SAMMPRIS trial [12]. In this trial (although focused on intracranial instead of extracranial stenosis) a strict medical management according to a previous published regimen [13,14] was able to mask any probable effect of additional interventional treatment of stenosis of intracranial arteries. Best medical treatment may be specified [15] as weight and girth loss by means of dietary counseling, lipid-lowering therapy (aimed at low-density lipoprotein level <2.6 mmol/l and a triglyceride <1.7 mmol/l and high-density lipoprotein level >1.0 mmol/l), smoking cessation (if applicable), blood pressure below 140/90 mm Hg (in case of diabetes or kidney disease, below 130/80 mm Hg) by means of antihypertensive agents and screening for diabetes and treatment (if applicable) with a target glycated hemoglobin level of less than 7% and a moderate-intensity aerobic physical exercise program (≥30 min most days of the week) however, treadmill testing should be performed in case of suspected coronary heart disease, that is present with high incidence in patients with carotid artery disease [16].
Prise de position de l'American Diabetes Association (ADA) et l'European Association for the Study of Diabetes (EASD)
2012, Medecine des Maladies Metaboliques